PMC:7205724 / 21808-23259 25 Projects
Annnotations
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T54390 | 0-3 | CD | denotes | 6.2 |
T7377 | 5-14 | VBG | denotes | Targeting |
T2754 | 15-31 | JJ | denotes | pro-inflammatory |
T79617 | 32-41 | NNS | denotes | cytokines |
T42975 | 43-48 | CD | denotes | 6.2.1 |
T96891 | 50-60 | NN | denotes | Hypothesis |
T41163 | 60-61 | -COLON- | denotes | : |
T35174 | 62-63 | DT | denotes | A |
T74401 | 64-67 | NN | denotes | mAb |
T75556 | 68-75 | IN | denotes | against |
T83617 | 76-79 | NN | denotes | IL6 |
T67953 | 80-83 | MD | denotes | can |
T68840 | 84-93 | VB | denotes | attenuate |
T2426 | 94-99 | NN | denotes | hyper |
T92661 | 100-112 | NN | denotes | inflammation |
T86439 | 113-124 | NNP | denotes | Tocilizumab |
T21494 | 124-125 | -COMMA- | denotes | , |
T50157 | 126-130 | RB | denotes | also |
T26283 | 131-136 | VBN | denotes | known |
T43571 | 137-139 | IN | denotes | as |
T44785 | 140-149 | NN | denotes | atlizumab |
T96810 | 149-150 | -COMMA- | denotes | , |
T58761 | 151-153 | VBZ | denotes | is |
T56416 | 154-155 | DT | denotes | a |
T79548 | 156-165 | JJ | denotes | humanized |
T29074 | 166-176 | JJ | denotes | anti-human |
T88685 | 177-180 | NN | denotes | IL6 |
T26777 | 181-189 | NN | denotes | receptor |
T24185 | 190-198 | NN | denotes | antibody |
T17221 | 199-207 | VBN | denotes | approved |
T32471 | 208-210 | IN | denotes | by |
T53882 | 211-214 | NNP | denotes | FDA |
T24580 | 215-218 | IN | denotes | for |
T33924 | 219-226 | JJ | denotes | several |
T90119 | 227-239 | JJ | denotes | inflammatory |
T59846 | 240-243 | CC | denotes | and |
T31666 | 244-254 | JJ | denotes | autoimmune |
T46803 | 255-263 | NNS | denotes | diseases |
T80969 | 264-270 | JJ | denotes | severe |
T13017 | 270-271 | -COMMA- | denotes | , |
T79015 | 272-276 | JJ | denotes | such |
T43255 | 277-279 | IN | denotes | as |
T47553 | 280-288 | NN | denotes | cytokine |
T34694 | 289-296 | NN | denotes | release |
T36705 | 297-305 | NN | denotes | syndrome |
T68837 | 305-306 | -COMMA- | denotes | , |
T30269 | 307-317 | JJ | denotes | rheumatoid |
T54700 | 318-327 | NN | denotes | arthritis |
T81658 | 327-328 | -COMMA- | denotes | , |
T84650 | 329-334 | JJ | denotes | giant |
T11095 | 335-339 | NN | denotes | cell |
T15987 | 340-349 | NN | denotes | arteritis |
T88887 | 349-350 | -COMMA- | denotes | , |
T31599 | 351-364 | JJ | denotes | polyarticular |
T93322 | 365-373 | JJ | denotes | juvenile |
T49595 | 374-384 | JJ | denotes | idiopathic |
T62141 | 385-394 | NN | denotes | arthritis |
T76737 | 394-395 | -COMMA- | denotes | , |
T30470 | 396-399 | CC | denotes | and |
T13999 | 400-410 | JJ | denotes | systematic |
T88238 | 411-419 | JJ | denotes | juvenile |
T89892 | 420-430 | JJ | denotes | idiopathic |
T97598 | 431-440 | NN | denotes | arthritis |
T25454 | 442-444 | PRP | denotes | It |
T28665 | 445-447 | VBZ | denotes | is |
T15312 | 448-452 | JJ | denotes | safe |
T18121 | 453-456 | CC | denotes | and |
T2467 | 457-466 | JJ | denotes | effective |
T39207 | 467-470 | IN | denotes | for |
T89869 | 471-475 | DT | denotes | both |
T32842 | 476-482 | NNS | denotes | adults |
T38357 | 483-486 | CC | denotes | and |
T13891 | 487-495 | NNS | denotes | children |
T61388 | 496-499 | CD | denotes | two |
T66576 | 500-505 | NNS | denotes | years |
T46590 | 506-508 | IN | denotes | of |
T15404 | 509-512 | NN | denotes | age |
T19164 | 513-516 | CC | denotes | and |
T99851 | 517-522 | JJR | denotes | older |
T41884 | 525-530 | CD | denotes | 6.2.2 |
T3706 | 532-541 | NNP | denotes | Rationale |
T87509 | 541-542 | -COLON- | denotes | : |
T72411 | 543-554 | NNP | denotes | Tocilizumab |
T46139 | 555-558 | MD | denotes | can |
T80638 | 559-564 | VB | denotes | treat |
T14365 | 565-569 | NN | denotes | lung |
T88114 | 570-576 | NN | denotes | injury |
T76208 | 577-579 | IN | denotes | in |
T24628 | 580-588 | NNS | denotes | patients |
T15777 | 589-593 | IN | denotes | with |
T58130 | 594-602 | JJ | denotes | critical |
T31522 | 603-606 | CC | denotes | and |
T55163 | 607-613 | JJ | denotes | severe |
T92225 | 614-622 | NN | denotes | COVID-19 |
T21073 | 623-625 | IN | denotes | In |
T65150 | 626-629 | DT | denotes | the |
T61991 | 630-635 | NN | denotes | study |
T18474 | 636-637 | -LRB- | denotes | [ |
T8341 | 637-639 | CD | denotes | 27 |
T6430 | 639-640 | -RRB- | denotes | ] |
T29393 | 640-641 | -COMMA- | denotes | , |
T77821 | 642-644 | CD | denotes | 21 |
T79215 | 645-653 | NNS | denotes | patients |
T5404 | 654-658 | IN | denotes | with |
T75582 | 659-667 | NN | denotes | COVID-19 |
T89299 | 668-673 | WP-DOLLAR- | denotes | whose |
T66055 | 674-683 | NN | denotes | condition |
T80340 | 684-687 | VBD | denotes | was |
T3490 | 688-694 | JJ | denotes | severe |
T44653 | 695-697 | CC | denotes | or |
T55941 | 698-706 | JJ | denotes | critical |
T85453 | 707-715 | VBD | denotes | received |
T98598 | 716-719 | CD | denotes | one |
T96881 | 720-722 | CC | denotes | or |
T24534 | 723-726 | CD | denotes | two |
T70238 | 727-732 | NNS | denotes | doses |
T20616 | 733-735 | IN | denotes | of |
T68912 | 736-747 | NNP | denotes | Tocilizumab |
T98192 | 748-752 | CC | denotes | plus |
T20706 | 753-761 | JJ | denotes | standard |
T58005 | 762-769 | NN | denotes | therapy |
T96625 | 771-779 | NNS | denotes | Patients |
T75572 | 780-783 | WP | denotes | who |
T31917 | 784-787 | VBD | denotes | had |
T15301 | 788-789 | DT | denotes | a |
T24848 | 790-794 | JJ | denotes | mean |
T84688 | 795-798 | NN | denotes | IL6 |
T96963 | 799-804 | NN | denotes | level |
T6930 | 805-807 | IN | denotes | of |
T90933 | 808-812 | JJR | denotes | more |
T81944 | 813-817 | IN | denotes | than |
T75581 | 818-827 | NN | denotes | 100 pg/ml |
T64021 | 828-834 | IN | denotes | before |
T9387 | 835-846 | NN | denotes | tocilizumab |
T84664 | 847-856 | NN | denotes | treatment |
T18203 | 857-863 | VBD | denotes | showed |
T60803 | 864-875 | NN | denotes | improvement |
T44490 | 876-878 | IN | denotes | in |
T81402 | 879-887 | JJ | denotes | clinical |
T14228 | 888-896 | NNS | denotes | symptoms |
T94537 | 897-900 | CC | denotes | and |
T83697 | 901-911 | JJ | denotes | peripheral |
T13978 | 912-918 | NN | denotes | oxygen |
T35808 | 919-929 | NN | denotes | saturation |
T34900 | 930-933 | CC | denotes | and |
T75964 | 934-947 | NN | denotes | normalization |
T84268 | 948-951 | IN | denotes | for |
T65028 | 952-962 | NN | denotes | lymphocyte |
T34390 | 963-973 | NN | denotes | proportion |
T96610 | 974-977 | CC | denotes | and |
T30755 | 978-981 | NN | denotes | CRP |
T63070 | 982-988 | NNS | denotes | levels |
T31791 | 990-994 | RB | denotes | Also |
T31152 | 994-995 | -COMMA- | denotes | , |
T79595 | 996-1000 | NN | denotes | lung |
T51431 | 1001-1007 | NN | denotes | lesion |
T10130 | 1008-1015 | NN | denotes | opacity |
T31388 | 1016-1019 | VBD | denotes | was |
T1824 | 1020-1028 | VBN | denotes | absorbed |
T60055 | 1029-1031 | IN | denotes | in |
T38598 | 1032-1034 | CD | denotes | 90 |
T67288 | 1034-1035 | NN | denotes | % |
T48683 | 1036-1038 | IN | denotes | of |
T41529 | 1039-1047 | NNS | denotes | patients |
T69670 | 1049-1056 | CC | denotes | Neither |
T9277 | 1057-1064 | JJ | denotes | serious |
T15021 | 1065-1072 | JJ | denotes | adverse |
T23626 | 1073-1080 | NNS | denotes | effects |
T98539 | 1081-1084 | CC | denotes | nor |
T65699 | 1085-1091 | NNS | denotes | deaths |
T50204 | 1092-1100 | VBD | denotes | occurred |
T20973 | 1101-1105 | IN | denotes | with |
T14012 | 1106-1117 | NN | denotes | tocilizumab |
T66286 | 1118-1127 | NN | denotes | treatment |
T24269 | 1129-1134 | EX | denotes | There |
T26765 | 1135-1138 | VBP | denotes | are |
T84711 | 1139-1146 | VBG | denotes | ongoing |
T74304 | 1147-1155 | JJ | denotes | clinical |
T68003 | 1156-1162 | NNS | denotes | trials |
T5000 | 1163-1166 | IN | denotes | for |
T64198 | 1167-1178 | NN | denotes | tocilizumab |
T83078 | 1179-1188 | NN | denotes | treatment |
T11331 | 1189-1191 | IN | denotes | in |
T42834 | 1192-1200 | NNS | denotes | patients |
T27205 | 1201-1205 | IN | denotes | with |
T23786 | 1206-1214 | JJ | denotes | moderate |
T45333 | 1215-1218 | CC | denotes | and |
T9137 | 1219-1225 | JJ | denotes | severe |
T27842 | 1226-1234 | NN | denotes | COVID-19 |
T92236 | 1236-1245 | RB | denotes | Currently |
T32112 | 1245-1246 | -COMMA- | denotes | , |
T54987 | 1247-1250 | DT | denotes | the |
T85855 | 1251-1254 | NN | denotes | use |
T69355 | 1255-1257 | IN | denotes | of |
T40115 | 1258-1269 | NNP | denotes | Tocilizumab |
T10850 | 1270-1272 | VBZ | denotes | is |
T78367 | 1273-1284 | VBN | denotes | recommended |
T33042 | 1285-1288 | IN | denotes | for |
T36466 | 1289-1297 | NNS | denotes | patients |
T61983 | 1298-1302 | IN | denotes | with |
T2749 | 1303-1311 | NN | denotes | COVID-19 |
T17580 | 1312-1315 | WP | denotes | who |
T69055 | 1316-1320 | VBP | denotes | have |
T71996 | 1321-1328 | VBG | denotes | warning |
T59356 | 1329-1334 | NNS | denotes | signs |
T65527 | 1335-1337 | IN | denotes | of |
T99769 | 1338-1343 | NN | denotes | hyper |
T44301 | 1344-1356 | NN | denotes | inflammation |
T54453 | 1356-1357 | -COMMA- | denotes | , |
T58078 | 1358-1360 | IN | denotes | as |
T75237 | 1361-1364 | MD | denotes | can |
T7496 | 1365-1367 | VB | denotes | be |
T53845 | 1368-1376 | VBN | denotes | measured |
T78207 | 1377-1379 | IN | denotes | by |
T88455 | 1380-1383 | NN | denotes | IL6 |
T77671 | 1383-1384 | -COMMA- | denotes | , |
T67481 | 1385-1393 | NN | denotes | ferritin |
T99390 | 1393-1394 | -COMMA- | denotes | , |
T23484 | 1395-1403 | NN | denotes | platelet |
T65701 | 1404-1410 | NNS | denotes | counts |
T30323 | 1410-1411 | -COMMA- | denotes | , |
T72053 | 1412-1424 | JJ | denotes | inflammatory |
T81575 | 1425-1432 | NNS | denotes | markers |
T96428 | 1432-1433 | -COMMA- | denotes | , |
T36542 | 1434-1437 | CC | denotes | and |
T88469 | 1438-1439 | NN | denotes | H |
T51141 | 1440-1445 | NN | denotes | score |
T97739 | 1446-1447 | -LRB- | denotes | [ |
T29313 | 1447-1449 | CD | denotes | 28 |
T54016 | 1449-1450 | -RRB- | denotes | ] |
R10896 | T63070 | T65028 | arg1Of | levels,lymphocyte |
R12091 | T60803 | T44490 | arg1Of | improvement,in |
R12170 | T62141 | T88887 | arg2Of | arthritis,"," |
R12475 | T15987 | T11095 | arg1Of | arteritis,cell |
R13130 | T30755 | T96610 | arg2Of | CRP,and |
R13146 | T26283 | T50157 | arg1Of | known,also |
R13154 | T85855 | T7496 | arg1Of | use,be |
R13264 | T44301 | T99769 | arg1Of | inflammation,hyper |
R13465 | T46803 | T33924 | arg1Of | diseases,several |
R14004 | T66055 | T89299 | arg1Of | condition,whose |
R14765 | T96891 | T68840 | arg1Of | Hypothesis,attenuate |
R15083 | T36542 | T96428 | arg1Of | and,"," |
R15531 | T77671 | T99390 | arg1Of | ",","," |
R16905 | T68003 | T84711 | arg1Of | trials,ongoing |
R17601 | T27842 | T27205 | arg2Of | COVID-19,with |
R18021 | T53882 | T17221 | arg1Of | FDA,approved |
R19206 | T53845 | T78207 | arg1Of | measured,by |
R19260 | T54700 | T68837 | arg2Of | arthritis,"," |
R19276 | T24185 | T56416 | arg1Of | antibody,a |
R19638 | T30470 | T76737 | arg1Of | and,"," |
R20598 | T55163 | T31522 | arg2Of | severe,and |
R20734 | T80969 | T24580 | arg2Of | severe,for |
R20864 | T81658 | T88887 | arg1Of | ",","," |
R21368 | T24628 | T15777 | arg1Of | patients,with |
R21524 | T24185 | T26777 | arg1Of | antibody,receptor |
R21619 | T34900 | T94537 | arg2Of | and,and |
R21959 | T36705 | T34694 | arg1Of | syndrome,release |
R21977 | T81575 | T30323 | arg2Of | markers,"," |
R22400 | T44301 | T65527 | arg2Of | inflammation,of |
R22449 | T98539 | T69670 | arg1Of | nor,Neither |
R2263 | T24185 | T88685 | arg1Of | antibody,IL6 |
R2282 | T67481 | T77671 | arg2Of | ferritin,"," |
R23852 | T97598 | T89892 | arg1Of | arthritis,idiopathic |
R24087 | T24185 | T79548 | arg1Of | antibody,humanized |
R24341 | T43255 | T79015 | arg1Of | as,such |
R24887 | T35808 | T13978 | arg1Of | saturation,oxygen |
R24950 | T38357 | T99851 | arg1Of | and,older |
R25403 | T3490 | T44653 | arg1Of | severe,or |
R26554 | T83078 | T5000 | arg2Of | treatment,for |
R2665 | T97598 | T13999 | arg1Of | arthritis,systematic |
R26904 | T85855 | T78367 | arg2Of | use,recommended |
R27191 | T23626 | T98539 | arg1Of | effects,nor |
R27294 | T1824 | T31388 | arg2Of | absorbed,was |
R27449 | T83078 | T64198 | arg1Of | treatment,tocilizumab |
R27501 | T51141 | T36542 | arg2Of | score,and |
R2759 | T62141 | T31599 | arg1Of | arthritis,polyarticular |
R27739 | T61991 | T21073 | arg2Of | study,In |
R27887 | T17221 | T24580 | arg1Of | approved,for |
R28465 | T23786 | T45333 | arg1Of | moderate,and |
R29264 | T44653 | T80340 | arg2Of | or,was |
R29518 | T68003 | T5000 | arg1Of | trials,for |
R29604 | T88114 | T80638 | arg2Of | injury,treat |
R30062 | T42834 | T27205 | arg1Of | patients,with |
R3039 | T79215 | T5404 | arg1Of | patients,with |
R31375 | T75582 | T5404 | arg2Of | COVID-19,with |
R32577 | T74401 | T41163 | arg2Of | mAb,: |
R33248 | T30470 | T43255 | arg2Of | and,as |
R33385 | T25454 | T15312 | arg1Of | It,safe |
R33791 | T99851 | T19164 | arg2Of | older,and |
R34037 | T68003 | T74304 | arg1Of | trials,clinical |
R34196 | T13891 | T38357 | arg2Of | children,and |
R35135 | T36466 | T69055 | arg1Of | patients,have |
R37231 | T98539 | T50204 | arg1Of | nor,occurred |
R37501 | T66576 | T61388 | arg1Of | years,two |
R37530 | T80638 | T46139 | arg2Of | treat,can |
R37793 | T96625 | T75572 | arg1Of | Patients,who |
R40933 | T36542 | T78207 | arg2Of | and,by |
R41615 | T51141 | T97739 | arg1Of | score,[ |
R41949 | T36705 | T68837 | arg1Of | syndrome,"," |
R42046 | T15987 | T84650 | arg1Of | arteritis,giant |
R42123 | T70238 | T85453 | arg2Of | doses,received |
R42821 | T97598 | T88238 | arg1Of | arthritis,juvenile |
R42879 | T98539 | T9277 | arg1Of | nor,serious |
R4444 | T31666 | T59846 | arg2Of | autoimmune,and |
R4477 | T92225 | T55163 | arg1Of | COVID-19,severe |
R44975 | T10130 | T1824 | arg2Of | opacity,absorbed |
R45357 | T36705 | T47553 | arg1Of | syndrome,cytokine |
R45661 | T90933 | T64021 | arg1Of | more,before |
R47508 | T97598 | T30470 | arg2Of | arthritis,and |
R48338 | T24185 | T58761 | arg2Of | antibody,is |
R48681 | T61991 | T18474 | arg1Of | study,[ |
R48731 | T59356 | T69055 | arg2Of | signs,have |
R4907 | T85855 | T10850 | arg1Of | use,is |
R49421 | T1824 | T60055 | arg1Of | absorbed,in |
R50655 | T88887 | T30470 | arg1Of | ",",and |
R50965 | T66286 | T14012 | arg1Of | treatment,tocilizumab |
R51850 | T94537 | T18203 | arg2Of | and,showed |
R52999 | T66055 | T80340 | arg1Of | condition,was |
R53041 | T58078 | T92236 | arg1Of | as,Currently |
R53068 | T96963 | T31917 | arg2Of | level,had |
R53187 | T96963 | T24848 | arg1Of | level,mean |
R5373 | T90933 | T6930 | arg2Of | more,of |
R53734 | T24534 | T96881 | arg2Of | two,or |
R54223 | T78367 | T10850 | arg2Of | recommended,is |
R5554 | T60803 | T94537 | arg1Of | improvement,and |
R56159 | T50204 | T20973 | arg1Of | occurred,with |
R56313 | T62141 | T93322 | arg1Of | arthritis,juvenile |
R56743 | T98192 | T20616 | arg2Of | plus,of |
R57258 | T90933 | T81944 | arg1Of | more,than |
R5731 | T70238 | T24534 | arg1Of | doses,two |
R57671 | T62141 | T49595 | arg1Of | arthritis,idiopathic |
R57903 | T63070 | T34390 | arg1Of | levels,proportion |
R58214 | T53882 | T32471 | arg2Of | FDA,by |
R58839 | T74401 | T75556 | arg1Of | mAb,against |
R59110 | T29313 | T97739 | arg2Of | 28,[ |
R59437 | T54700 | T30269 | arg1Of | arthritis,rheumatoid |
R59576 | T9137 | T45333 | arg2Of | severe,and |
R60119 | T36466 | T17580 | arg1Of | patients,who |
R60586 | T65701 | T99390 | arg2Of | counts,"," |
R60939 | T90119 | T59846 | arg1Of | inflammatory,and |
R61251 | T2749 | T61983 | arg2Of | COVID-19,with |
R61440 | T58005 | T98192 | arg2Of | therapy,plus |
R61441 | T58078 | T32112 | arg1Of | as,"," |
R6154 | T59356 | T65527 | arg1Of | signs,of |
R61551 | T14228 | T81402 | arg1Of | symptoms,clinical |
R62752 | T34900 | T84268 | arg1Of | and,for |
R63345 | T18121 | T28665 | arg2Of | and,is |
R64318 | T65699 | T98539 | arg2Of | deaths,nor |
R6462 | T44785 | T43571 | arg2Of | atlizumab,as |
R64820 | T96891 | T41163 | arg1Of | Hypothesis,: |
R65301 | T58761 | T96810 | arg1Of | is,"," |
R65601 | T70238 | T20616 | arg1Of | doses,of |
R65763 | T25454 | T28665 | arg1Of | It,is |
R65895 | T24185 | T29074 | arg1Of | antibody,anti-human |
R66809 | T14228 | T44490 | arg2Of | symptoms,in |
R66943 | T85855 | T54987 | arg1Of | use,the |
R66954 | T24269 | T26765 | arg1Of | There,are |
R67132 | T70238 | T98598 | arg1Of | doses,one |
R67692 | T75964 | T34900 | arg2Of | normalization,and |
R68271 | T30323 | T36542 | arg1Of | ",",and |
R69456 | T24628 | T76208 | arg2Of | patients,in |
R69719 | T79617 | T2754 | arg1Of | cytokines,pro-inflammatory |
R71645 | T15312 | T18121 | arg1Of | safe,and |
R71674 | T85855 | T75237 | arg1Of | use,can |
R72696 | T83617 | T75556 | arg2Of | IL6,against |
R72772 | T59356 | T71996 | arg1Of | signs,warning |
R72983 | T78367 | T54453 | arg1Of | recommended,"," |
R74424 | T98598 | T96881 | arg1Of | one,or |
R74784 | T68840 | T67953 | arg2Of | attenuate,can |
R74963 | T79215 | T85453 | arg1Of | patients,received |
R75326 | T85453 | T21073 | arg1Of | received,In |
R75716 | T54390 | T7377 | arg1Of | 6.2,Targeting |
R75826 | T96963 | T15301 | arg1Of | level,a |
R76104 | T41529 | T48683 | arg2Of | patients,of |
R76550 | T58130 | T31522 | arg1Of | critical,and |
R76769 | T92225 | T58130 | arg1Of | COVID-19,critical |
R76811 | T26283 | T43571 | arg1Of | known,as |
R77190 | T66576 | T19164 | arg1Of | years,and |
R77316 | T54016 | T97739 | arg3Of | ],[ |
R77360 | T38357 | T89869 | arg1Of | and,both |
R77534 | T24185 | T17221 | arg2Of | antibody,approved |
R78022 | T66055 | T55941 | arg1Of | condition,critical |
R78333 | T32842 | T38357 | arg1Of | adults,and |
R78533 | T42834 | T11331 | arg2Of | patients,in |
R78642 | T84664 | T9387 | arg1Of | treatment,tocilizumab |
R79228 | T79215 | T77821 | arg1Of | patients,21 |
R79527 | T74401 | T35174 | arg1Of | mAb,A |
R79687 | T92225 | T15777 | arg2Of | COVID-19,with |
R79824 | T2467 | T18121 | arg2Of | effective,and |
R79844 | T68837 | T81658 | arg1Of | ",","," |
R79916 | T84664 | T64021 | arg2Of | treatment,before |
R79941 | T66286 | T20973 | arg2Of | treatment,with |
R80450 | T8341 | T18474 | arg2Of | 27,[ |
R80686 | T66576 | T46590 | arg1Of | years,of |
R81194 | T55941 | T44653 | arg2Of | critical,or |
R81304 | T38357 | T39207 | arg2Of | and,for |
R8185 | T96625 | T18203 | arg1Of | Patients,showed |
R81985 | T1824 | T31791 | arg1Of | absorbed,Also |
R8244 | T63070 | T84268 | arg2Of | levels,for |
R82868 | T86439 | T26283 | arg2Of | Tocilizumab,known |
R82985 | T80638 | T76208 | arg1Of | treat,in |
R82994 | T61991 | T65150 | arg1Of | study,the |
R83125 | T86439 | T21494 | arg1Of | Tocilizumab,"," |
R83390 | T51141 | T88469 | arg1Of | score,H |
R84073 | T96891 | T67953 | arg1Of | Hypothesis,can |
R84172 | T75582 | T89299 | arg2Of | COVID-19,whose |
R84332 | T3706 | T87509 | arg1Of | Rationale,: |
R84932 | T53845 | T7496 | arg2Of | measured,be |
R85183 | T98539 | T15021 | arg1Of | nor,adverse |
R85448 | T38357 | T66576 | arg1Of | and,years |
R85482 | T78367 | T58078 | arg1Of | recommended,as |
R85705 | T67288 | T38598 | arg1Of | %,90 |
R86004 | T72411 | T46139 | arg1Of | Tocilizumab,can |
R86212 | T46803 | T90119 | arg1Of | diseases,inflammatory |
R86934 | T18121 | T39207 | arg1Of | and,for |
R87485 | T46803 | T31666 | arg1Of | diseases,autoimmune |
R87538 | T85855 | T53845 | arg2Of | use,measured |
R87665 | T25454 | T2467 | arg1Of | It,effective |
R88261 | T96963 | T84688 | arg1Of | level,IL6 |
R88299 | T63070 | T30755 | arg1Of | levels,CRP |
R89076 | T88455 | T77671 | arg1Of | IL6,"," |
R89241 | T27842 | T23786 | arg1Of | COVID-19,moderate |
R89881 | T85855 | T69355 | arg1Of | use,of |
R89899 | T68912 | T98192 | arg1Of | Tocilizumab,plus |
R8993 | T65701 | T23484 | arg1Of | counts,platelet |
R89954 | T67288 | T60055 | arg2Of | %,in |
R9002 | T3706 | T41884 | arg1Of | Rationale,6.2.2 |
R90450 | T10130 | T31388 | arg1Of | opacity,was |
R90482 | T88114 | T14365 | arg1Of | injury,lung |
R90538 | T46803 | T80969 | arg1Of | diseases,severe |
R90654 | T66055 | T3490 | arg1Of | condition,severe |
R90774 | T35808 | T34900 | arg1Of | saturation,and |
R90910 | T1824 | T31152 | arg1Of | absorbed,"," |
R91084 | T67288 | T48683 | arg1Of | %,of |
R91228 | T96625 | T31917 | arg1Of | Patients,had |
R91756 | T86439 | T58761 | arg1Of | Tocilizumab,is |
R92122 | T81575 | T72053 | arg1Of | markers,inflammatory |
R92175 | T15404 | T46590 | arg2Of | age,of |
R92198 | T72411 | T80638 | arg1Of | Tocilizumab,treat |
R92270 | T96891 | T42975 | arg1Of | Hypothesis,6.2.1 |
R92393 | T35808 | T83697 | arg1Of | saturation,peripheral |
R92489 | T40115 | T69355 | arg2Of | Tocilizumab,of |
R92565 | T99390 | T30323 | arg1Of | ",","," |
R92610 | T24185 | T43255 | arg1Of | antibody,as |
R92720 | T36466 | T61983 | arg1Of | patients,with |
R93465 | T79617 | T7377 | arg2Of | cytokines,Targeting |
R93944 | T78367 | T33042 | arg1Of | recommended,for |
R94262 | T68003 | T26765 | arg2Of | trials,are |
R94310 | T53845 | T58078 | arg2Of | measured,as |
R94369 | T75581 | T81944 | arg2Of | 100 pg/ml,than |
R94556 | T92661 | T68840 | arg2Of | inflammation,attenuate |
R95470 | T83078 | T11331 | arg1Of | treatment,in |
R96088 | T96963 | T6930 | arg1Of | level,of |
R96842 | T53845 | T75237 | arg2Of | measured,can |
R96846 | T15987 | T81658 | arg2Of | arteritis,"," |
R96954 | T36466 | T33042 | arg2Of | patients,for |
R97104 | T27842 | T9137 | arg1Of | COVID-19,severe |
R97168 | T34390 | T96610 | arg1Of | proportion,and |
R97353 | T58005 | T20706 | arg1Of | therapy,standard |
R97819 | T17221 | T13017 | arg1Of | approved,"," |
R98220 | T85453 | T29393 | arg1Of | received,"," |
R98822 | T92661 | T2426 | arg1Of | inflammation,hyper |
R9904 | T10130 | T51431 | arg1Of | opacity,lesion |
R99138 | T10130 | T79595 | arg1Of | opacity,lung |
R99891 | T6430 | T18474 | arg3Of | ],[ |